Names and pronunciation
(peg-as′par-jase) Oncaspar
PDF page 1027
Loading InternPractice…
Drug reference
(peg-as′par-jase) Oncaspar
PDF page 1027
Func. class.: Antineoplastic agent, miscellaneous
PDF page 1027
USES: Treatment of acute lympho- blastic leukemia (ALL) with hypersensi- tivity to L-asparaginase (multiagent chemotherapy); first-line treatment of ALL (combination chemotherapy)
PDF page 1027
CONTRAINDICATIONS Hypersensitivity, serious thrombosis with prior L-asparaginase therapy; pancreati- tis; serious hemorrhagic events with prior L-asparaginase therapy; severe hepatic disease
PDF page 1027
DOSAGE AND ROUTES Acute lymphoblastic leukemia (ALL), as first-line treatment or in patients with hypersensitivity to native asparaginase Adult: IM, IV: ≤21 yr: 2500 units/m2 (as part of a multiagent combination chemo- P therapy regimen); do not administer more frequently than every 14 days; >21 yr: 2000 units/m2 (as part of a multiagent combina- tion chemotherapy regimen); do not ad- minister more frequently than every 14 days Acute lymphoblastic leukemia (ALL) Infant/child/adolescent: IM, IV: 2500 units/ m2/dose (combination chemotherapy); do not use more frequently than q14 days
PDF page 1027
Available forms: Injection 3750 IU/5 mL in single-use vials HIGH ALERT
PDF page 1027